Oculis候选药Privosegtor获FDA临床试验许可,可推进急性多发性硬化复发临床开发

瑞士生物制药公司 Oculis Holding AG(纳斯达克代码:OCS)11月16日宣布,美国食品药品监管局(FDA)已批准其候选药 Privosegtor 用于急性多发性硬化(MS)复发的新药临床试验(IND)申请,该药由此可以在这项新适应症上启动临床开发。
据该公司介绍,FDA 神经病学二部在此前的临床试验申请前沟通中确认,Oculis 可以交叉引用 Privosegtor 已经开启的眼科方向临床试验申请数据。FDA 同时支持该公司提出的临床开发策略:把出现视神经炎的多发性硬化患者以及其他类型的复发患者(如行走功能受影响的复发)都纳入研究,主要终点最早可设在三个月,剂量沿用 PIONEER-1 研究的方案,为每日每公斤体重3毫克、连用五天。
这项推进建立在二期 ACUITY 研究的结果之上。该研究在视神经炎患者中显示,Privosegtor 具有神经保护效果,改善了患者的视觉功能,保住了视网膜神经节细胞层的完整,并降低了血液中反映轴突损伤的神经丝轻链与反映星形胶质细胞活化的胶质纤维酸性蛋白两项指标。Oculis 首席执行官 Riad Sherif 表示,这次许可标志着 Privosegtor 从视神经炎迈向急性多发性硬化复发,针对的是目前尚无获批神经保护疗法的高需求领域。
多发性硬化是一种中枢神经系统的慢性自身免疫疾病,全球患者约280万人,美国约85万人,美国每年估计发生约17万次复发。急性复发的现有处理主要靠大剂量皮质类固醇缩短发作时间,长期治疗则靠免疫调节药物减少复发频率,两类办法都没有被证明能直接保护神经元与轴突。Privosegtor 此前已就视神经炎适应症获得 FDA 的突破性疗法认定、欧洲药品管理局的优先药物认定,以及两家机构的孤儿药认定,目前正在 PIONEER 注册性研究项目中接受评估;该药仍属在研药物,尚未在任何国家获批上市。
Oculis 总部位于瑞士 Zug,在美国与欧洲设有运营机构。该公司计划于12月8日举行研发日,介绍 Privosegtor 在急性多发性硬化复发上的关键性开发计划,以及 PIONEER 项目在视神经病变方面的最新进展。
(来源:Oculis)
FDA Clears Oculis' Privosegtor IND to Advance Clinical Development in Acute Multiple Sclerosis Relapses
Oculis Holding AG (Nasdaq: OCS), a Swiss biopharmaceutical company, announced on November 16 that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its candidate Privosegtor for the treatment of acute multiple sclerosis (MS) relapses, allowing clinical development to begin in the new indication.
According to the company, in pre-IND feedback the FDA Division of Neurology-2 confirmed that Oculis can cross-reference data from the open Privosegtor ophthalmology-related IND. The FDA also supported the proposed clinical development strategy, which would include MS patients who experience optic neuritis as well as other types of relapses, such as ambulatory relapses, with a primary endpoint as early as three months and the same dose used in PIONEER-1, 3 mg/kg daily for five days.
The expansion builds on the Phase 2 ACUITY study in optic neuritis, in which Privosegtor showed a neuroprotective effect, improved visual function, preserved the retinal ganglion cell layer, and reduced blood levels of neurofilament light chain, a biomarker of axonal injury, and glial fibrillary acidic protein, a biomarker of astrocytic activation. Oculis Chief Executive Officer Dr. Riad Sherif said the IND clearance marks Privosegtor's advance from optic neuritis into acute MS relapses, a high-unmet-need setting with no currently approved neuroprotective therapies.
Multiple sclerosis is a chronic autoimmune disease of the central nervous system affecting approximately 2.8 million people worldwide, including around 850,000 in the United States, where an estimated 170,000 relapses occur each year. Current treatment of acute relapses relies mainly on high-dose corticosteroids to shorten the episode, while long-term immunomodulators reduce relapse frequency; neither approach has been proven to directly protect neurons and axons. Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for optic neuritis, and is being evaluated in the PIONEER registrational program. It remains an investigational drug and has not been approved in any country.
Oculis is headquartered in Zug, Switzerland, with operations in the United States and Europe. The company plans to host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and on the PIONEER program in optic neuropathies.
(Source: Oculis)
来源:Oculis
发布:GSM·美国(发布链接)
图片来源:图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story

